Zimmer Biomet (ZBH) Projected to Announce Quarterly Earnings on Wednesday

Zimmer Biomet (NYSE:ZBH) is anticipated to post its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect the company to post earnings of $1.88 per share and revenue of $2.04 billion for the quarter. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 8:30 AM ET.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share for the quarter, topping analysts’ consensus estimates of $2.01 by $0.06. The company had revenue of $2.18 billion during the quarter, compared to the consensus estimate of $2.13 billion. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%. The business’s quarterly revenue was up 4.8% on a year-over-year basis. During the same period last year, the business earned $2.07 EPS. On average, analysts expect Zimmer Biomet to post $8.54 EPS for the current fiscal year and $8.98 EPS for the next fiscal year.

Zimmer Biomet Stock Up 2.9%

Shares of Zimmer Biomet stock opened at $97.27 on Tuesday. The firm has a market cap of $18.55 billion, a price-to-earnings ratio of 11.37, a P/E/G ratio of 2.32 and a beta of 0.49. The stock has a 50-day simple moving average of $94.79 and a 200-day simple moving average of $91.74. Zimmer Biomet has a 52-week low of $79.12 and a 52-week high of $103.70. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.69 and a quick ratio of 0.94.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, October 30th. Investors of record on Wednesday, September 30th were given a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 1.0%. The ex-dividend date of this dividend was Wednesday, September 30th. Zimmer Biomet’s dividend payout ratio (DPR) is presently 23.36%.

Insider Buying and Selling

In other Zimmer Biomet news, insider Kevin R. Thornal sold 5,691 shares of the company’s stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $92.95, for a total transaction of $528,978.45. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Chad F. Phipps sold 3,000 shares of the stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $98.35, for a total value of $295,050.00. Following the transaction, the insider owned 65,231 shares in the company, valued at approximately $6,415,468.85. This trade represents a 4.40% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 1.28% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the stock. Barclays upgraded shares of Zimmer Biomet to a “hold” rating in a research note on Wednesday, October 7th. Canaccord Genuity Group boosted their target price on shares of Zimmer Biomet from $83.00 to $100.00 and gave the stock a “hold” rating in a research report on Monday, August 10th. Sanford C. Bernstein increased their price target on shares of Zimmer Biomet from $91.00 to $93.00 and gave the stock a “market perform” rating in a research note on Thursday, August 6th. Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a report on Wednesday, August 5th. Finally, Stifel Nicolaus raised their price target on shares of Zimmer Biomet from $105.00 to $110.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Seven equities research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $104.47.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc is a medical technology company that develops and manufactures products used in orthopedic surgery and musculoskeletal care. Its portfolio includes implants for the hip, knee, shoulder, and other joints, as well as products for sports medicine, extremity reconstruction, trauma, and spine procedures.

The company also offers surgical technologies and solutions designed to support orthopedic procedures, including robotic-assisted surgery systems, digital tools, patient-specific planning, and related instruments.